In a familiar story line, investors in Big Pharma have a drug-pricing problem. This time, however, the script has flipped. The drug industry is a standard punching bag for politicians, and that shouldn’t be any different as a new election cycle begins. As usual, a swath of the industry chose to raise prices of older medicines as the calendar turned to 2019. The increases were mostly modest, though a few were double-digit-percentage price boosts.

Source: Wall Street Journal January 02, 2019 18:10 UTC